Do analysts prefer ATHX or DCOY?

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 293.70%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Athersys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ATHX or DCOY more profitable?

Athersys' return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Decoy Therapeutics N/A -395.42% -193.30%

Which has stronger earnings & valuation, ATHX or LABT?

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than Athersys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Lakewood-Amedex Biotherapeutics N/A N/A N/A N/A N/A

Is ATHX or LABT more profitable?

Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Which has better valuation & earnings, ATHX or VCNX?

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Vaccinex $388K 6.84 -$20.25M -$48.27 N/A

Is ATHX or VCNX more profitable?

Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Vaccinex N/A N/A -383.58%

Which has stronger valuation & earnings, ATHX or ORGS?

Orgenesis has higher revenue and earnings than Athersys. Orgenesis is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Orgenesis $662K 3.12 -$55.36M -$11.51 N/A

Is ATHX or ORGS more profitable?

Athersys has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Orgenesis -3,827.81% N/A -130.18%

Do analysts rate ATHX or CANF?

Can-Fite BioPharma has a consensus target price of $42.50, suggesting a potential upside of 817.93%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Athersys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is ATHX or CANF more profitable?

Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Can-Fite BioPharma N/A N/A N/A

Athersys (ATHX) Competitors

Compare

ATHX vs. DCOY, LABT, VCNX, ORGS, and CANF

Should you buy Athersys stock or one of its competitors? MarketBeat compares Athersys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athersys include Decoy Therapeutics (DCOY), Lakewood-Amedex Biotherapeutics (LABT), Vaccinex (VCNX), Orgenesis (ORGS), and Can-Fite BioPharma (CANF).

How does Athersys compare to Decoy Therapeutics?

Athersys (NASDAQ:ATHX) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Athersys has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

In the previous week, Decoy Therapeutics had 8 more articles in the media than Athersys. MarketBeat recorded 8 mentions for Decoy Therapeutics and 0 mentions for Athersys. Decoy Therapeutics' average media sentiment score of 0.47 beat Athersys' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Athersys	Neutral
Decoy Therapeutics	Neutral

Athersys' return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Decoy Therapeutics	N/A	-395.42%	-193.30%

19.4% of Athersys shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 293.70%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Decoy Therapeutics has lower revenue, but higher earnings than Athersys. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Summary

Decoy Therapeutics beats Athersys on 9 of the 14 factors compared between the two stocks.

How does Athersys compare to Lakewood-Amedex Biotherapeutics?

Athersys (NASDAQ:ATHX) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

19.4% of Athersys shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lakewood-Amedex Biotherapeutics had 9 more articles in the media than Athersys. MarketBeat recorded 9 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Athersys. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.87 beat Athersys' score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Athersys	Neutral
Lakewood-Amedex Biotherapeutics	Positive

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than Athersys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

Summary

Athersys and Lakewood-Amedex Biotherapeutics tied by winning 3 of the 6 factors compared between the two stocks.

How does Athersys compare to Vaccinex?

Athersys (NASDAQ:ATHX) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Vaccinex	$388K	6.84	-$20.25M	-$48.27	N/A

In the previous week, Vaccinex had 1 more articles in the media than Athersys. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for Athersys. Athersys' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Vaccinex	Neutral

19.4% of Athersys shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 0.0% of Athersys shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Vaccinex	N/A	N/A	-383.58%

Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Summary

Vaccinex beats Athersys on 6 of the 9 factors compared between the two stocks.

How does Athersys compare to Orgenesis?

Athersys (NASDAQ:ATHX) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

19.4% of Athersys shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Athersys' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Orgenesis	Neutral

Orgenesis has higher revenue and earnings than Athersys. Orgenesis is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market. Comparatively, Orgenesis has a beta of 2.89, meaning that its share price is 189% more volatile than the broader market.

Athersys has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Orgenesis	-3,827.81%	N/A	-130.18%

Summary

Orgenesis beats Athersys on 6 of the 9 factors compared between the two stocks.

How does Athersys compare to Can-Fite BioPharma?

Athersys (NASDAQ:ATHX) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Can-Fite BioPharma has a consensus target price of $42.50, suggesting a potential upside of 817.93%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Can-Fite BioPharma had 5 more articles in the media than Athersys. MarketBeat recorded 5 mentions for Can-Fite BioPharma and 0 mentions for Athersys. Athersys' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Can-Fite BioPharma	Neutral

19.4% of Athersys shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Can-Fite BioPharma has higher revenue and earnings than Athersys. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Can-Fite BioPharma	$405K	7.49	-$7.63M	-$35.80	N/A

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Can-Fite BioPharma	N/A	N/A	N/A

Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Summary

Can-Fite BioPharma beats Athersys on 10 of the 12 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHX vs. The Competition

Export

Metric	Athersys	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$833K	$788.54M	$6.79B	$12.59B
Dividend Yield	N/A	4.84%	2.66%	6.14%
P/E Ratio	0.00	1.52	27.41	25.27
Price / Sales	N/A	118.11	530.69	99.42
Price / Cash	N/A	20.06	47.99	59.26
Price / Book	N/A	8.17	11.04	6.62
Net Income	-$72.53M	-$3.96M	$3.57B	$336.83M

Athersys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHX Athersys	N/A	N/A	N/A	N/A	$833K	$146K	N/A	24
DCOY Decoy Therapeutics	2.9736 of 5 stars	$5.91 -1.6%	$30.00 +407.9%	N/A	$3.19M	N/A	N/A	20	Gap Down
LABT Lakewood-Amedex Biotherapeutics	N/A	$3.72 -6.3%	N/A	N/A	$2.60M	N/A	N/A	5	Short Interest Increase
VCNX Vaccinex	N/A	$0.83 flat	N/A	+36.0%	$2.16M	$388K	N/A	40	Gap Up
ORGS Orgenesis	N/A	$0.40 -19.2%	N/A	-73.9%	$2.07M	$662K	N/A	150	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHX) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athersys (ATHX) Competitors

ATHX vs. DCOY, LABT, VCNX, ORGS, and CANF

How does Athersys compare to Decoy Therapeutics?

Summary

How does Athersys compare to Lakewood-Amedex Biotherapeutics?

Summary

How does Athersys compare to Vaccinex?

Summary

How does Athersys compare to Orgenesis?

Summary

How does Athersys compare to Can-Fite BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athersys (ATHX) Competitors

ATHX vs. DCOY, LABT, VCNX, ORGS, and CANF

How does Athersys compare to Decoy Therapeutics?

Which has more volatility and risk, ATHX or DCOY?

Does the media favor ATHX or DCOY?

Is ATHX or DCOY more profitable?

Do institutionals & insiders have more ownership in ATHX or DCOY?

Do analysts prefer ATHX or DCOY?

Which has higher earnings and valuation, ATHX or DCOY?

Summary

How does Athersys compare to Lakewood-Amedex Biotherapeutics?

Do insiders and institutionals hold more shares of ATHX or LABT?

Does the media prefer ATHX or LABT?

Which has stronger earnings & valuation, ATHX or LABT?

Is ATHX or LABT more profitable?

Summary

How does Athersys compare to Vaccinex?

Which has better valuation & earnings, ATHX or VCNX?

Does the media prefer ATHX or VCNX?

Do insiders and institutionals hold more shares of ATHX or VCNX?

Is ATHX or VCNX more profitable?

Which has more volatility & risk, ATHX or VCNX?

Summary

How does Athersys compare to Orgenesis?

Do insiders and institutionals believe in ATHX or ORGS?

Does the media refer more to ATHX or ORGS?

Which has stronger valuation & earnings, ATHX or ORGS?

Which has more volatility and risk, ATHX or ORGS?

Is ATHX or ORGS more profitable?

Summary

How does Athersys compare to Can-Fite BioPharma?

Do analysts rate ATHX or CANF?

Does the media favor ATHX or CANF?

Do insiders and institutionals hold more shares of ATHX or CANF?

Which has better earnings & valuation, ATHX or CANF?

Is ATHX or CANF more profitable?

Which has more risk and volatility, ATHX or CANF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools